Neumirna Therapeutics
neumirna.com
Biotechnology
Neurology & CNS Therapeutics
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer
COPENHAGEN, Denmark, September 18, 2025--Neumirna Therapeutics, a biotechnology company developing RNA-based therapies for neurological diseases, today announced the appointment of Ellen K. Donnelly, Ph.D. as Chief Executive Officer.
Read more
Report
Neumirna Therapeutics: €20 Million (Series A) Raised To Develop RNA Therapies For Neurological Disorders
Neumirna Therapeutics - an RNA-focused biotech company developing next-generation therapeutics for neurological disorders - announced the first closing of its Series A funding round at €20 million. New investors Angelini Ventures and Invivo Partners co-le
Read more
Report
Angelini Ventures co-leads €20 million Series A financing in Neumirna Therapeutics to Develop Next-Generation RNA Therapeutics for Epilepsy and other Neurological Disorders
Angelini Ventures co-leads alongside Invivo Partners with participation from Innovestor's Life Science Fund and other existing investors Financing will support clinical development of Neumirna's lead asset NMT.001, a potential disease-modifying Antisense
Read more
Report